Boehringer Ingelheim, Eli Lilly Resubmit NDA for Diabetes DrugBy
Boehringer Ingelheim Pharmaceuticals, Inc. and
The Class 1 resubmission follows a complete response letter issued by the
The drug was developed as part of the diabetes alliance between Boehringer Ingelheim and Eli Lilly, which was formed in January 2011.
Source: Eli Lilly